Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gynecologic 3

Conditions

Sarcoma 1568Glioblastoma 512Gliosarcoma 485Osteosarcoma 458Brain Neoplasms 344Gastrointestinal Stromal Tumors 324Central Nervous System Neoplasms 296Neoplasms 291Dendritic Cell Sarcoma, Interdigitating 286Astrocytoma 275Lymphoma 259Bone Neoplasms 243Breast Neoplasms 237Sarcoma, Ewing 236Glioma 236Neuroblastoma 230Rhabdomyosarcoma 226Melanoma 224Precursor Cell Lymphoblastic Leukemia-Lymphoma 218Recurrence 216Lymphoma, Non-Hodgkin 216Burkitt Lymphoma 213Oligodendroglioma 203Ovarian Neoplasms 200Lymphoma, Large B-Cell, Diffuse 187Neoplasm Metastasis 186Lymphoma, Follicular 172Leukemia 164Leukemia, Lymphocytic, Chronic, B-Cell 158Hodgkin Disease 158

Interventions

temsirolimus 1Sorafenib 1Sirolimus 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrent Uterine Sarcoma × Sarcoma × Clear all
NCT00075400 2019-07-24

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
26 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

NCT01061606 2016-11-09

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

National Cancer Institute (NCI)

Phase 2 Terminated
8 enrolled 6 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

NCT00238121 2015-11-20

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡